DOTTIKON EXCLUSIVE SYNTHESIS AG
DOTTIKON EXCLUSIVE SYNTHESIS AG is a drug establishment in Dottikon, Switzerland, registered with the US FDA under FEI 3002806909. Its registered operations are: Analytical testing, API manufacture. 3 EU/UK GMP certificates are matched to this site, 2 inspected within the last three years.
Sources: FDA Drug Establishments Current Registration Site (checked 2 Nov 2026); EudraGMDP; MHRA GMDP. Methodology
Registered operations
Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.
GMP documents matched to this site (3)
| Document | Authority | Inspection | Source |
|---|---|---|---|
DE_BW_01_GMP_2026_0096 GMP certificate | Competent authority of Germany | 5 Mar 2026 within 3-year review window | EudraGMDP |
GMPE-CH-1006978 GMP certificate | Competent authority of Switzerland | 7 Feb 2025 within 3-year review window | EudraGMDP |
GMPE-CH-1005034 GMP certificate | Competent authority of Switzerland | 10 Feb 2022 outside 3-year review window | EudraGMDP |
A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.
What this page does not show
- Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
- Capacity, scale, price or current availability: no regulator publishes these.
- FDA inspection classifications for this site, which are not yet linked.